Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment

• Published in: Investigative and clinical urology Vol. 58; no. 1; pp. 42 - 47
• Main Authors: Kim, Aram, Lee, Kyu-Sung, Kim, Tae Beom, Kim, Hyung Joon, Yoo, Eun Sang, Yun, Jong-Hyun, Kim, Duk Yoon, Jung, Suk Gun, Lee, Jun Taik, Kim, Jung Man, Oh, Cheol Kyu, Shin, Ju Hyun, Jeon, Seung Hyun, Lee, Seong Ho, Han, Chang Hee, Lee, Dong Hwan, Cho, Hyuk Jin, Choo, Myung-Soo
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Urological Association 2017; Korean Urological Association; 대한비뇨의학회
• Subjects: Aged; Antimuscarinic treatment; Overactive bladder; Recurrence; Female; Humans; Male; Middle Aged; Muscarinic Antagonists - therapeutic use; Original; Prospective Studies; Quality of Life; Recurrence; Risk Factors; Symptom Assessment; Urinary Bladder, Overactive - complications; Urinary Bladder, Overactive - drug therapy; Withholding Treatment; 비뇨기과학; Recurrence; Overactive bladder; Antimuscarinic treatment
• ISSN: 2466-0493; 2466-054X; 2466-054X
• DOI: 10.4111/icu.2017.58.1.42

To identify incidence and risk factors of recurrence after discontinuation of successful antimuscarinic therapy in patients with overactive bladder (OAB). This was a prospective, multicenter trial. Patients who had antimuscarinic agents for more than 12 weeks and showed successful response were enrolled. Successful response was defined as answering 'benefit' for patient perception of treatment benefit and answer lesser than 3 points in patient's perception of bladder condition (PPBC). The enrolled patients discontinued the antimuscarinics, and we evaluated their recurrence with PPBC and OAB symptom score (OABSS) at 1, 3, 6, and 12 months. Primary purpose was to identify the recurrence rate and secondary purpose was to reveal risk factors. Four hundred forty-one patients enrolled and 371 patients completed 6-month follow-up. The enrolled patients showed 1.6 points in PPBC, 2.9 points in OABSS and 1.4 points in IPSS (quality of life) which represented successful response after using antimuscarinics. The cumulative rates of recurrence were 25.6%, 42.3%, and 52.2% at 1, 3, 6 months, respectively. Among 177 patients who did not show recurrence at 6 months, 41 patients were followed up and 4 patients of the 41 patients (9.7%) showed recurrence at 12 months. On univariate and multivariate analyses of recurrence, OAB wet was the risk factor for recurrence after 6 months of discontinuation. Discontinuation of antimuscarinic therapy after successful treatment resulted in high recurrence rate with time and OAB wet was the independent risk factor for recurrence.